Proceeds from overseas price increases by Pfizer (PFE.US) will be shared with the US government: the “Most-Favored Nation” contract has been revealed, and more than 20 transactions are still confidential

The Zhitong Finance App learned that, according to reports, if Pfe.US (PFE.US) can raise overseas drug prices, the US Department of Health and Human Services (HHS) will get a portion of the increased revenue from this.

The “most favored nation” (most favored nation) contract was announced last Saturday (September 19) by the consumer rights monitoring organization “Public Citizen” (Public Citizen) — the organization obtained the contract after filing a Freedom of Information Act (Freedom of Information Act) lawsuit. According to reports, the organization has published documents relating to the Pfizer and LLY.US (LLY.US) contract, and the remaining 20 or more transactions are still confidential.

Reports show that the contract indicates that Pfizer agreed to share a portion of its net incremental revenue from overseas price increases with HHS. This provision applies to marketed drugs and is valid from January 1, 2026 to January 20, 2029. The revenue share ratio, the drugs involved, and other details have all been blacked out and abridged.

According to the report, White House spokesman Kush Desai (Kush Desai) said in a statement: “President Trump has made it very clear that this is not a one-way street: foreign drug prices will rise, and American patients will no longer have to bear the burden of paying for global innovation alone. The purpose of these overseas revenue provisions is to ensure that the incremental revenue from overseas price increases benefits American patients, not pharmaceutical companies.”